Minimal Residual Disease

CHICAGO — In this video, Adam Cohen, MD, spoke to Healio about the use of minimal residual disease testing to determine cessation of therapy in patients with multiple myeloma.

An FDA advisory committee unanimously voted minimal residual disease should be an accepted endpoint for accelerated approval of clinical trials investigating treatments for patients with multiple myeloma.

Among elderly patients with acute myeloid leukemia, survival outcomes for those who received an allogenic stem cell transplant have improved significantly over the past 2 decades, according to data published in Clinical Cancer Research.

In this video, Eunice Wang, MD discusses acute myeloid leukemia highlights from the ASH Annual Meeting and Exposition.

SAN DIEGO — A combination of targeted therapies used for a response-directed duration significantly improved outcomes compared with chemoimmunotherapy for fit patients with untreated chronic lymphocytic leukemia, according to study results.

Outcomes among children with acute myeloid leukemia treated with high-dose cytarabine-based regimens did not vary by race, according to study results presented at ASH Annual Meeting and Exposition.

Patients with multiple myeloma who exhibited sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel achieved longer PFS and duration of response, according to study results.

In this video, Nikhil Munshi, MD, Professor of Medicine at Harvard Medical School, discusses the importance of awareness for multiple myeloma and how it relates to the disease's changing treatment landscape.

In this video, Eunice Wang, MD, discussed a retrospective analysis looking at outcomes of chimeric antigen receptor T-cell therapy for patients diagnosed with B-cell acute lymphoblastic leukemia, presented at ASCO Annual Meeting.

NEW ORLEANS — In this video perspective, Richard M. Stone, MD, discusses research results on blinatumomab presented at ASH Annual Meeting and Exposition.